brian leedman

Psivida: A Biotech Platform With Great Potential (PSDV)

Thanks David, although the article does not mention the 4 evaluation agreements with 3 of the top 5 pharmas and 1 evaluation agreement with a large medical device company plus, potential for new licensing deals on BrachySil and possible significant revenues from the sale of Retisert in the US by the end of the year. Any of these could see the share price rise, substantially. Perhaps these points could be considered for your next article on pSivida.

Brian Leedman, Investor Relations, pSivida